Imprimis pharmaceuticals news

Imprimis also said it discontinued a Phase III program for Impracor, a topical cream formulation of 10% ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), that uses Accudel technology. In August, Imprimis said it would delay the start of a double-blind, placebo-controlled, U.S. Phase III trial of Impracor to treat acute pain associated with osteoarthritis (OA) of the knee. The company said it will consider alternative commercialization pathways for Impracor, which may include an improvement of its formulation (see BioCentury, Sept. 2). ...